Nonsteroidal Anti-Inflammatory Drugs as PPARγ Agonists Can Induce PRODH/POX-Dependent Apoptosis in Breast Cancer Cells: New Alternative Pathway in NSAID-Induced Apoptosis.
Anti-Inflammatory Agents, Non-Steroidal
/ pharmacology
Antineoplastic Agents
/ pharmacology
Apoptosis
Breast Neoplasms
/ drug therapy
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Collagen
/ biosynthesis
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
MCF-7 Cells
Oxidative Phosphorylation
/ drug effects
PPAR gamma
/ agonists
Proline
/ metabolism
Proline Oxidase
/ metabolism
Reactive Oxygen Species
/ metabolism
COX
NSAIDS
PPAR
apoptosis
breast cancer
oxidative stress
proline
proline dehydrogenase
proline oxidase
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jan 2022
28 Jan 2022
Historique:
received:
31
12
2021
revised:
25
01
2022
accepted:
26
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered to be therapeutics in cancer prevention because of their inhibitory effect on cyclooxygenases (COX), which are frequently overexpressed in many types of cancer. However, it was also demonstrated that NSAIDs provoked a proapoptotic effect in COX knocked-out cancer cells. Here, we suggest that this group of drugs may provoke antineoplastic activity through the activation of PPARγ, which induces proline dehydrogenase/proline oxidase (PRODH/POX)-dependent apoptosis. PRODH/POX is a mitochondrial enzyme that catalyzes proline degradation, during which ATP or reactive oxygen species (ROS) are generated. We have found that NSAIDs induced PRODH/POX and PPARγ expressions (as demonstrated by Western Blot or immunofluorescence analysis) and cytotoxicity (as demonstrated by MTT, cytometric assay, and DNA biosynthesis assay) in breast cancer MCF7 cells. Simultaneously, the NSAIDs inhibited collagen biosynthesis, supporting proline for PRODH/POX-induced ROS-dependent apoptosis (as demonstrated by an increase in the expression of apoptosis markers). The data suggest that targeting proline metabolism and the PRODH/POX-PPARγ axis can be considered a novel approach for breast cancer treatment.
Identifiants
pubmed: 35163433
pii: ijms23031510
doi: 10.3390/ijms23031510
pmc: PMC8835909
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antineoplastic Agents
0
PPAR gamma
0
Reactive Oxygen Species
0
Collagen
9007-34-5
Proline
9DLQ4CIU6V
Proline Oxidase
EC 1.5.3.-
PRODH protein, human
EC 1.5.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Centre
ID : 2017/27/N/NZ7/02370
Références
Autophagy. 2012 Sep;8(9):1407-9
pubmed: 22885468
Clin Cancer Res. 2005 Mar 1;11(5):1999-2007
pubmed: 15756026
Pharmaceuticals (Basel). 2021 Aug 29;14(9):
pubmed: 34577574
Med Hypotheses. 2000 Feb;54(2):210-5
pubmed: 10790755
Biochem Biophys Res Commun. 2008 May 2;369(2):308-13
pubmed: 18279664
Front Oncol. 2013 Jul 11;3:181
pubmed: 23875171
Carcinogenesis. 2005 Aug;26(8):1335-42
pubmed: 15817612
FASEB J. 2001 Dec;15(14):2742-4
pubmed: 11606477
Rheumatol Int. 2012 Jun;32(6):1491-502
pubmed: 22193214
Biochim Biophys Acta. 2007 Aug;1771(8):915-25
pubmed: 17317294
Clin Chim Acta. 1982 Oct 27;125(2):193-205
pubmed: 7139961
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Cancer Cell Int. 2010 Apr 26;10:11
pubmed: 20420667
Curr Pharm Des. 2015;21(21):2978-82
pubmed: 26004413
Oncogene. 2010 Sep 2;29(35):4914-24
pubmed: 20562915
Oncogene. 2008 Dec 4;27(53):6729-37
pubmed: 18794809
Oncology. 1999 Oct;57 Suppl 2:17-26
pubmed: 10545799
Int J Mol Sci. 2020 Apr 09;21(7):
pubmed: 32283655
J Clin Oncol. 2005 Jan 10;23(2):254-66
pubmed: 15637389
Lancet. 2010 Nov 20;376(9754):1741-50
pubmed: 20970847
Oncol Rep. 2005 Apr;13(4):559-83
pubmed: 15756426
Cancer Res. 2001 Mar 15;61(6):2424-8
pubmed: 11289109
Oncogene. 2006 Sep 14;25(41):5640-7
pubmed: 16619034
Front Oncol. 2012 Jun 21;2:60
pubmed: 22737668
JAMA. 2005 Aug 24;294(8):914-23
pubmed: 16118381
PLoS One. 2014 Dec 31;9(12):e114633
pubmed: 25551641
Chem Biol Drug Des. 2016 Jul;88(1):17-25
pubmed: 26841308
Oncotarget. 2017 Apr 18;8(16):26819-26831
pubmed: 28460464
J Clin Med. 2021 Oct 10;10(20):
pubmed: 34682765
Biochim Biophys Acta. 2011 Aug;1812(8):1007-22
pubmed: 21382489
Mol Cell Biochem. 2007 Jan;295(1-2):85-92
pubmed: 16874462
Nature. 1997 Sep 18;389(6648):300-5
pubmed: 9305847
Nat Commun. 2017 Dec 12;8(1):2052
pubmed: 29233996
Nat Rev Cancer. 2012 Feb 09;12(3):181-95
pubmed: 22318237
Cancer Res. 2001 Mar 1;61(5):1810-5
pubmed: 11280728
Int J Mol Sci. 2018 Nov 09;19(11):
pubmed: 30424016
Curr Drug Targets. 2015;16(13):1464-9
pubmed: 26553010
Jpn J Cancer Res. 1999 Jan;90(1):75-80
pubmed: 10076568
Biochem Biophys Res Commun. 2003 Jul 11;306(4):887-97
pubmed: 12821125
Clin Cancer Res. 2014 Mar 1;20(5):1104-13
pubmed: 24311630
Theriogenology. 2017 Oct 1;101:53-61
pubmed: 28708516
J Nutr. 2008 Oct;138(10):2008S-2015S
pubmed: 18806116
Cell Biol Int. 2018 Aug;42(8):949-958
pubmed: 29512256
Nucl Recept Signal. 2015 Oct 05;13:e004
pubmed: 26445566
Breast Cancer Res Treat. 2012 Feb;132(1):51-9
pubmed: 21533532
Biochem Pharmacol. 1996 Jul 26;52(2):237-45
pubmed: 8694848
Bioorg Med Chem. 2016 Nov 1;24(21):5455-5461
pubmed: 27622746
J Biol Chem. 2006 Jan 27;281(4):2044-52
pubmed: 16303758
Biochemistry. 2018 Jun 26;57(25):3433-3444
pubmed: 29648801
Antioxid Redox Signal. 2019 Feb 1;30(4):635-649
pubmed: 28990419
Cancer Res. 1987 Feb 15;47(4):936-42
pubmed: 3802100
Curr Drug Targets. 2019;20(3):302-315
pubmed: 30073924
Int J Cell Biol. 2012;2012:723419
pubmed: 22505934
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Stem Cells Int. 2016;2016:2048731
pubmed: 27882058
Cancers (Basel). 2020 Jan 06;12(1):
pubmed: 31935820